Clinical Trials: Page 7
-
Getty Images
Muscle-building drug improves body composition in obesity trial, Veru says
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
By Jonathan Gardner • Jan. 27, 2025 -
Getty Images
Novo shares climb on early data for dual-acting obesity drug
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.
By Jonathan Gardner • Jan. 24, 2025 -
Explore the Trendline➔
Getty Images
TrendlineOncology's research boom
More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.
By BioPharma Dive staff -
Getty Images
Immune resetIGM’s autoimmune pivot backfires as top drug disappoints in testing
The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.
By Ben Fidler • Jan. 9, 2025 -
Sean Gallup via Getty Images
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.
By Delilah Alvarado • Jan. 9, 2025 -
Getty Images
Metsera reveals data supporting long-acting obesity shot
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug as a future threat to weight loss medicines from Novo Nordisk and Eli Lilly.
By Jonathan Gardner • Jan. 7, 2025 -
Mario Tama via Getty Images
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.
By Ned Pagliarulo • Jan. 7, 2025 -
Getty Images
ALS drug developmentALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
By Jacob Bell • Jan. 7, 2025 -
Getty Images
Neumora plummets on depression drug data
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.”
By Jacob Bell • Jan. 2, 2025 -
Kendall Davis/BioPharma Dive
Tracker10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and AATD headline a series of study results that could give the biotechnology sector a boost.
By BioPharma Dive staff • Updated June 30, 2025 -
Courtesy of Novo Nordisk
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
By Jonathan Gardner • Updated Dec. 20, 2024 -
Getty Images
Roche sticks with Parkinson’s drug despite second study failure
Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the drug, which it’s been developing with Prothena for more than a decade.
By Jacob Bell • Dec. 19, 2024 -
Getty Images
Regeneron says study data support big bet on new blood thinners
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.
By Jonathan Gardner • Dec. 19, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.
By Jacob Bell • Dec. 19, 2024 -
Getty Images
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
By Ben Fidler • Dec. 17, 2024 -
Getty Images
Maternal mortality trends are dire — and reversing them remain an uphill battle
Rising maternal mortality, particularly among vulnerable groups, has roots in insufficient research involving pregnant women.
By Michael Gibney • Dec. 17, 2024 -
Spencer Platt via Getty Images
Edgewise weighs fast approval path for muscular dystrophy drug
The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.
By Ned Pagliarulo • Dec. 16, 2024 -
Getty Images
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.
By Jonathan Gardner • Dec. 16, 2024 -
Michael M. Santiago via Getty Images
Keros shares collapse on ‘unanticipated’ setback for lung disease drug
Safety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to BioPharma Dive data.
By Kristin Jensen • Dec. 12, 2024 -
Getty Images
With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.
By Jonathan Gardner • Updated Dec. 11, 2024 -
ASH/Todd Buchanan
ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T
Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, answers remained elusive on Pfizer's abrupt withdrawal of Oxbryta.
By Ned Pagliarulo • Dec. 10, 2024 -
Getty Images
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned class of heart medicines called CETP inhibitors.
By Ben Fidler • Dec. 10, 2024 -
Courtesy of Matt Herp / American Society of Hematology
ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH mid-stage findings for important new medicines.
By Ned Pagliarulo , Jonathan Gardner , Ben Fidler • Dec. 9, 2024 -
Getty Images
Deep DiveEndometriosis drug research, long underfunded, confronts familiar problems in women’s health
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By Delilah Alvarado • Dec. 9, 2024 -
Scott Olson via Getty Images
Obesity drugsLilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
By Jonathan Gardner • Updated Dec. 4, 2024 -
Getty Images
Obesity drugsAmgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
By Jonathan Gardner • Nov. 26, 2024
Previous
